Anluray, Cherryl B.
HRN: 21-71-16 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/21/2022
CO-AMOXICLAV 625MG (TAB)
07/21/2022
07/28/2022
PO
625
BId
Cleft Palate
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes